<?xml version='1.0' encoding='utf-8'?>
<document id="25708617"><sentence text="Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators." /><sentence text="Early lead compounds in this gamma secretase modulator series were found to potently inhibit CYP3A4 and other human CYP isoforms increasing their risk of causing drug-drug-interactions (DDIs)" /><sentence text=" Using structure-activity relationships and CYP3A4 structural information, analogs were developed that minimized this DDI potential" /><sentence text=" Three of these new analogs were further characterized by rat PK, rat PK/PD and rat exploratory toxicity studies resulting in selection of SPI-1865 (14) as a preclinical development candidate" /><sentence text=" " /></document>